Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPN | P05981 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3454507 | 0.89 | CYP2D6 (0.44) | CYP2D6CYP1A2CYP3A4ALDH1A1LMNA | |
| SCHEMBL4578793 | 0.86 | ALDH1A1 (0.49) | CYP2D6CYP1A2CYP3A4ALDH1A1LMNA | |
| SCHEMBL14780181 | 0.86 | TSHR (0.45) | CYP2D6CYP1A2CYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL2754706 | 0.84 | ALDH1A1 (0.51) | CYP2D6CYP1A2CYP3A4ALDH1A1LMNA | |
| SCHEMBL6586026 | 0.84 | ALDH1A1 (0.51) | CYP2D6CYP1A2CYP3A4ALDH1A1LMNA | |
| SCHEMBL22262634 | 0.83 | HPN (0.38) | HPNCYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL22262431 | 0.82 | HPN (0.40) | HPNCYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL22262236 | 0.82 | HPN (0.40) | HPNCYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23145905 | 0.81 | CYP2D6 (0.41) | CYP2D6CYP1A2CYP3A4ALDH1A1LMNA | |
| SCHEMBL30335196 | 0.79 | HPN (0.39) | HPNCYP2D6CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041737-A1 | 5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | Novartis AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-05-06 | — | — | US | disclosed |
| EP-2882749-B1 | 4-METHYL-2,3,5,9,9B-PENTAAZA-CYCLOPENTA[A]NAPHTHALENES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-04 | — | — | EP | disclosed |
| US-9085584-B2 | Substituted pyrido[3,2-E][1,2,4]-triazolo[4,3-A]pyrazines for the treatment of central nervous system disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-21 | — | — | US | disclosed |
| US-9085584-B2 | Substituted pyrido[3,2-E][1,2,4]-triazolo[4,3-A]pyrazines for the treatment of central nervous system disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-21 | — | — | US | disclosed |
| US-9085584-B2 | Substituted pyrido[3,2-E][1,2,4]-triazolo[4,3-A]pyrazines for the treatment of central nervous system disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-21 | — | — | US | disclosed |
| US-20140045857-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045856-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045857-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045857-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045856-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045856-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045857-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | PDE12, PDE2A, PDE3A | HPN 2297/4885CYP2D6 236/4885CYP1A2 18/4885 |
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | HPN 4840/4885CYP2D6 958/4885CYP1A2 568/4885 |
| US-20140045856-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | PDE12, PDE2A, PDE3A | HPN 2297/4885CYP2D6 236/4885CYP1A2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.